References
- Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311:806–814.
- Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol. 2013;9:13–27.
- Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–846.
- Cefalu WT, Bray GA, Home PD, et al. Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors’ expert forum. Diabetes Care. 2015;38:1567–1582.
- Twig G, Yaniv G, Levine H, et al. Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood. New England J Med. 2016;374:2430–2440.
- Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342–362.
- Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–154.
- O’Brien PE. Bariatric surgery: mechanisms, indications and outcomes. J Gastroenterol Hepatol. 2010;25:1358–1365.
- Leung WY, Thomas GN, Chan JC, et al. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther. 2003;25:58–80.
- Halpern B, Halpern A. Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications. Expert Opin Drug Saf. 2015;14:305–315.
- DiNicolantonio JJ, Chatterjee S, O’Keefe JH, et al. Lorcaserin for the treatment of obesity? A closer look at its side effects. Open Heart. 2014;1:e000173.
- Singh J, Kumar R. Phentermine-topiramate: first combination drug for obesity. Int J Appl Basic Med Res. 2015;5:157–158.
- Neoh SL, Sumithran P, Haywood CJ, et al. Combination phentermine and topiramate for weight maintenance: the first Australian experience. Med J Aust. 2014;201:224–226.
- Verpeut JL, Bello NT. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert Opin Drug Saf. 2014;13:831–841.
- Caixas A, Albert L, Capel I, et al. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther. 2014;8:1419–1427.
- Center for Drug Evaluation and Research. Application number: 200063Orig1s000. 2014 Sep 10 [cited 2016 Jun 28]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000SumR.pdf.
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–1439.
- Holst JJ, Deacon CF. Is there a place for incretin therapies in obesity and prediabetes? Trends Endocrinol Metab. 2013;24:145–152.
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157.
- Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Investig. 2014;124:4223–4226.
- Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.
- Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8:738–742.
- Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194–206.
- Unniappan S, McIntosh CH, Demuth HU, et al. Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY. Diabetologia. 2006;49:1915–1923.
- Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care. 2007;30:1335–1343.
- Habegger KM, Heppner KM, Geary N, et al. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010;6:689–697.
- Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21:27–36.
- Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155:1280–1290.
- Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995;358:219–224.
- Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs in Context. 2015;4:212283. doi:10.7573/dic.212283
- Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–2276.
- Buteau J, El-Assaad W, Rhodes CJ, et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia. 2004;47:806–815.
- De Marinis YZ, Salehi A, Ward CE, et al. GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. Cell Metab. 2010;11:543–553.
- Fineman MS, Cirincione BB, Maggs D, et al. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab. 2012;14:675–688.
- Hare KJ, Vilsboll T, Asmar M, et al. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes. 2010;59:1765–1770.
- Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:2719–2725.
- Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981–E988.
- Shirazi R, Palsdottir V, Collander J, et al. Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proc Natl Acad Sci U S A. 2013;110:16199–16204.
- Sisley S, Gutierrez-Aguilar R, Scott M, et al. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest. 2014;124:2456–2463
- Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124:4473–4488
- Kanoski SE, Hayes MR, and Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310:R885–R895
- Farr OM, Sofopoulos M, Tsoukas MA, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia. 2016;59:954–965.
- van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014;38:784–793.
- Meier JJ, Gethmann A, Gotze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006;49:452–458.
- Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110:26–37.
- Smilowitz NR, Donnino R, Schwartzbard A. Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease. Circulation. 2014;129:2305–2312.
- Tate M, Chong A, Robinson E, et al. Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol. 2015;172:721–736.
- Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788–1803.
- Consoli A, Formoso G. Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opin Drug Saf. 2015;14:207–218.
- Trahair LG, Horowitz M, Stevens JE, et al. Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes. Diabetologia. 2015;58:1769–1778.
- Cho YM, Merchant CE, Kieffer TJ. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther. 2012;135:247–278.
- Lund A, Knop FK, Vilsboll T. Emerging GLP-1 receptor agonists. Expert Opin Emerg Dr. 2011;16:607–618.
- Lund A, Knop FK, Vilsboll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med. 2014;25:407–414.
- Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742.
- Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes. Metab. 2016;18:317–332.
- Yabe D, Kuwata H, Usui R, et al. Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points. Curr Med Res Opin. 2015;31:1267–1270.
- Bray GA. Obesity: liraglutide–another weapon in the war against obesity? Nat Rev Endocrinol. 2015;11:569–570.
- Iepsen EW, Torekov SS, Holst JJ. Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther. 2015;13:753–767.
- Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–1616.
- Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843–854.
- Lean ME, Carraro R, Finer N, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond). 2014;38:689–697.
- Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond). 2013;37:1443–1451.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.
- Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314:687–699.
- Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond). 2016;40:1310–1319.
- Jensterle M, Pirs B, Goricar K, et al. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study. Eur J Clin Pharmacol. 2015;71:817–824.
- de Luis DA, Aller R, de la Fuente B, et al. Relation of the rs6923761 gene variant in glucagon-like peptide 1 receptor with weight, cardiovascular risk factor, and serum adipokine levels in obese female subjects. J Clin Lab Anal. 2015;29:100–105.
- de Luis DA, Ovalle HF, Soto GD, et al. Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2. J Investig Med. 2014;62:324–327.
- Malone J, Trautmann M, Wilhelm K, et al. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2009;18:359–367.
- Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010;33:1173–1175.
- Dushay J, Gao C, Gopalakrishnan GS, et al. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care. 2012;35:4–11.
- Christensen M, Knop FK, Vilsboll T, et al. Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs. 2011;20:549–557.
- Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
- Anderson SL, Trujillo JM. Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. Ther Adv Chronic Dis. 2016;7:4–17.
- Tomlinson B, Hu M, Zhang Y, et al. An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opin Inv Drug. 2016;25:145–158.
- Sanford M. Dulaglutide: first global approval. Drugs. 2014;74:2097–2103.
- Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287–296.
- Umpierrez GE, Pantalone KM, Kwan AY, et al. Relationship between weight change and glycaemic control with once weekly dulaglutide treatment in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:615–622.
- Scheen AJ. Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. Expert Rev Clin Pharmacol. 2016;9:385–399.
- Zhang L, Zhang M, Zhang Y, et al. Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Sci Rep. 2016;6:18904.
- Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349–1357.
- Bronden A, Naver SV, Knop FK, et al. Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opin Drug Metab Toxicol. 2015;11:1493–1503.
- Fisher M, Petrie MC, Ambery PD, et al. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol. 2015;3:697–703.
- Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289–297.
- Egan JM, Chia CW. Incretin therapy and pancreatic pathologies: background pathology versus drug-induced pathology in rats. Diabetes. 2014;63:1174–1178.
- Monami M, Dicembrini I, Nardini C, et al. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Res Clin Pr. 2014;103:269–275.
- Rosenstock J, Balas B, Charbonnel B, et al. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care. 2013;36:498–504.
- Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.
- Finan B, Clemmensen C, Muller TD. Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists. Mol Cell Endocrinol. 2015;418 Pt 1:42–54.
- Henry RR, Rosenstock J, Logan D, et al. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complications. 2014;28:393–398.
- Baron MA, Buse J, Azeem R, et al. A randomised, double-blind, placebo-controlled, 39 week trial of ITCA 650 as add-on therapy in type 2 diabetes. Diabetologia. 2015;58:S55–S55.
- Henry RR, Rosenstock J, Denham D, et al. Efficacy and tolerability of ITCA 650 (continuous subcutaneous exenatide) for 39 weeks in patients with poorly controlled type 2 diabetes mellitus and high baseline HbA(1c) (>10%). Diabetologia. 2015;58:S378.
- Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58:7370–7380.
- Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39:231–241.
- Sorli C, Harashima S-I, Tsoukas G, et al. OR15-1 efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1). 98th Annual Meeting of the Endocrine Society (ENDO); 2016 Apr 6; Boston.
- Novo Nordisk successfully completes first phase 3a trial with semaglutide in people with type 2 diabetes. [ cited 2015 Oct 19]. Available from: http://globenewswire.com/news-release/2015/07/10/751271/0/en/Novo-Nordisk-successfully-completes-first-phase-3a-trial-with-semaglutide-in-people-with-type-2-diabetes.html.
- Idris I. Novo Nordisk announced successful results from the 4th phase 3a trial with semaglutide in people with type 2 diabetes. Diabetes Obes Metab. 2016;18:312–313.
- Nordisk N. Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial; 2016 28 Apr [cited 2016 Jun 28]. Available from: http://www.novonordisk.com/bin/getPDF.2007805.pdf.
- Steinert RE, Poller B, Castelli MC, et al. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin Pharmacol Ther. 2009;86:644–650.
- NN9924 ClinicalTrials. [ cited 2015 Oct 19]. Available from: https://clinicaltrials.gov/ct2/results?term=NN9924&Search=Search.
- Jabbour S, Pieber TR, Rosenstock J, et al. Robust dose-dependent glucose lowering and body weight (BW) reductions with the novel oral formulation of semaglutide in patients with early type 2 diabetes (T2D) [Abstract OR15-3]. 98th Annual Meeting of the Endocrine Society (ENDO); 2016 Apr 6; Boston.
- Novo Nordisk, Inc [Internet]. [cited 2016 Jun 28]. Available from: http://globenewswire.com/news-release/2015/08/26/763616/0/en/Novo-Nordisk-to-initiate-phase-3a-development-of-oral-semaglutide-a-once-daily-oral-GLP-1-analogue.html#sthash.f7lHmS2H.dpuf.
- HM11260C, a new generation long acting super GLP-1R agonist with a unique pharmacokinetic profile improves glucose control and GI tolerability; a phase IIa clinical trial in T2DM [Abstract]. Presented at the 49th EASD Annual Meeting; 2013 Sep 23-27; Barcelona, Spain. [cited 2015 Oct 16]. Available from: http://www.hanmipharm.com/ehanmi/img/rnd/2013_EASD_(HM11260C).pdf.
- Pharmacokinetics and pharmacodynamic effects of a single dose of the long-acting GLP-1R agonist LAPS-Exendin-4 in subjects with type 2 diabetes mellitus [Abstract]. Presented at the American Diabetes Association (ADA) 72th Scientific Sessions; 2012 June 8-12; Philadelphia, Pennsylvania, USA. [cited 2015 Oct 16]. Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=07aff962-bab8-4955-800c-f731d933d91d&cKey=76ef8c10-53b3-44fa-9693-835292943472&mKey=0f70410f-8df3-49f5-a63d-3165359f5371.
- Dose-response improvements in glycemic control and body weight reductions with HM11260C, a once-weekly GLP-1 receptor agonist with liraglutide as reference, in type 2 diabetes (T2DM) [Abstract]. Presented at the American Diabetes Association (ADA) 75th Scientific Sessions; 2015 Jun 5-9; Boston, USA. [cited 2015 Oct 16]. Available from: http://app.core-apps.com/tristar_ada15/abstract/160858d53930b598d64b10f393f8374d.
- Significant effects of HM11260C on body weight over 20 weeks in obese subjects without diabetes: a randomized, double-blind, placebo-controlled study [Abstract]. Presented at the American Diabetes Association (ADA) 75th Scientific Sessions; 2015 Jun 5-9; Boston, USA. [cited 2015 Oct 16]. Available from: http://app.core-apps.com/tristar_ada15/abstract/1678f29f2a56ce35baedcc25f3959e9d.
- Significant effects of HM11260C (efpeglenatide) on body weight over 20 weeks in obese subjects without diabetes: a randomized, double-blind, placebo controlled study. 51st European Association for the Study of Diabetes (EASD) Annual Meeting; 2015 Sep 14– 8; Stockholm, Sweden.
- Once-a-month treatment with HM11260C improves glycemic control in type 2 diabetes (T2DM)—interim data from a 16-week study [Abstract]. Presented at the American Diabetes Association (ADA) 75th Scientific Sessions; 2015 Jun 5-9; Boston, USA. cited 2015 Oct 16]. Available from: http://app.core-apps.com/tristar_ada15/abstract/1678f29f2a56ce35baedcc25f391fbb5.
- Weekly subcutaneous doses of glymera (PB1023) a novel GLP-1 analogue reduce glucose exposure dose-dependently [Abstract]. Presented at the American Diabetes Association (ADA) 72th Scientific Sessions; 2012 Jun 8-12; Philadelphia, PA, USA. [cited 2015 Oct 16]. Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=761b96ad-5b5d-4d0c-80d2-a7cb9c3b63fa&cKey=657f214c-9b3b-4072-aaa5-d48f4dfca4f7&mKey=0f70410f-8df3-49f5-a63d-3165359f5371.
- PB1023 for Type 2 Diabetes [Internet]. [cited 2016 Jun 28]. Available from: http://www.phasebio.com/pages/pipeline/pb1023.php.
- TTP054, a novel, orally-available glucagon-like peptide-1 (GLP-1) agonist, lowers hba1c in subjects with type 2 diabetes mellitus (T2DM) [Abstract]. Presented at the American Diabetes Association (ADA) 74th Scientific Sessions; 2014 Jun 13-17; San Francisco, CA, USA. [cited 19 Oct 2015]. Available from: http://app.core-apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc8638a09fb8.
- TTP273, an orally-available glucagon-like peptide-1 (GLP-1) agonist, notably reduces glycemia in subjects with type 2 diabetes mellitus [Abstract] Presented at the American Diabetes Association (ADA) 74th Scientific Sessions; 2014 Jun 13-17; San Francisco, CA, USA. [cited 2015 19 Oct]. Available from: http://app.core-apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc8638a09315.
- vTv Therapeutics. [ cited 2015 Oct 19]. Available from: http://vtvtherapeutics.com/pipeline/ttp273.
- CJC-1134-PC. [ cited 2015 Oct 19]. Available from: http://www.conjuchem.com/pipeline/cjc-1134-pc.
- Schellenberger V, Wang CW, Geething NC, et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. 2009;27:1186–1190.
- A monthly dosed GLP-1 analog for treatment of type 2 diabetes mellitus [Abstract] Presented at the American Diabetes Association (ADA) 70th Scientific Sessions; 2010 Jun 25-29; Orlando, FL, USA. [cited 2015 Oct 19]. Available from: http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=79329.
- ZYOG1. A novel orally efficacious peptidomimetic GLP-1 receptor agonist. [Abstract] Presented at the American Diabetes Association (ADA) 72nd Scientific Sessions; 2012 Jun 8–12; Philadelphia (PA). Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=4bd51c7e-2511-42a3-8442-aa513907e675&cKey=46e180af-270d-4da3-87a4-9fad4ff624eb&mKey=0f70410f-8df3-49f5-a63d-3165359f5371
- Novo Nordisk company announcement. 2014 Oct 30. Available from: https://www.novonordisk.com/bin/getPDF.1866957.pdf.
- ARI-1732TS, a long acting, protease resistant, orally active GLP-1 analog [Abstract]. Presented at Diabetes Summit;2015 Apr 27-29; Boston, USA. [cited 2015 Oct 19]. Available from: http://www.giiconference.com/gtc321496/diabetes-drug-discovery-development-agenda.shtml.
- Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6:19–28.
- Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344;d7771.
- Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36:2288–2296.
- James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905–917.
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
- Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495–502.
- Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638–1642.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
- Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015;38:1161–1172.